Abstract Library

#2972 Characteristics and Management of Paragangliomas, 10 Years Experience

Introduction: Paraganglioma (PG) is a rare extra-adrenal neuroendocrine tumor, with common sites of presentation being abdomen, and head and neck region. The majority of PGs appear to be sporadic. However, almost half of cases are associated with an inherited syndrome. The highest malignancy rates are seen in paragangliomas (PGs) associated with SDHB mutations, which are usually abdominal and secretory.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Sardo E, Cameselle-Garcia S, Casteras A, Toledo R, Acosta D,

Keywords: Paraganglioma, SDHB mutations, Functioning Tumors,

#2853 Succinate Dehydrogenase B (SDHB) Immunohistochemical Expression in Pancreatic Neuroendocrine Tumours and Correlation with Somatostatin Receptor Immunohistochemistry

Introduction: The established category of succinate dehydrogenase (SDH) deficient neoplasms includes several endocrine tumours with recent evidence that pancreatic neuroendocrine tumours (PNETs) could be included in this tumour group. The SDH complex is composed of four subunits (A-D) but loss of immunohistochemical (IHC) expression for SDHB indicates bi-allelic inactivation of any SDH component and is used as a marker for syndromic disease.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Swan N

Authors: Swan N, Nadeem N, Crowley R,

Keywords: succinate dehydrogenase, pancreatic neuroendocrine tumor, somatostatin receptor, immunohistochemistry,

#1833 Peptide Receptor Radionuclide Therapy in a Patient with SDHB Related Grade 3 Paraganglioma (PGL) of Urinary Bladder

Introduction: SDHB mutation cause aggressive metastatic PGL.36% of patients survive 5 yrs,treatment options are limited & many still being evaluated

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Steyn R, Prasad V,

Keywords: SDHB, Bladder PGL, PRRT ,

#1784 Peptide Receptor Radionuclide Therapy (PRRT) for Treatment of Functional and Metastatic Phaeochromocytoma (PCC) and Paraganglioma (PGL)

Introduction: Treatment options for metastatic PCC/PGL and related hypertension (HTN) are limited. Experiences in PRRT suggest favourable disease control, but lack of data on HTN response.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: kong G

Authors: Kong G, Grozinsky-Glasberg S, Callahan J, Hofman M, Meirovitz A,

Keywords: PRRT,

#1640 SDHB Mutation in a Young Patient with a Metastatic Paraganglioma of the Urinary Bladder

Introduction: Paragangliomas are rare tumors that arise from the sympathetic and parasympathetic ganglia that can possess an inherited trait.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Lambrescu I, Cima L, Leca B, Martin S, Fica S,

Keywords: paragangliomas, SDHB mutation,